Product
Infliximab
Aliases
AVSOLA, Flixabi, IFX, Inflectra (4 other aliases)
Name
REMICADE
INN Name
INFLIXIMAB
FDA Approved
Yes
53 clinical trials
6 organizations
62 indications
5 documents
Indication
ArthritisIndication
RheumatoidIndication
Ankylosing spondylitisIndication
PsoriaticIndication
Crohn's diseaseIndication
ColitisIndication
UlcerativeIndication
PsoriasisIndication
Crohn's DiseaseIndication
DepressionIndication
MajorIndication
InflammationIndication
Inflammatory Bowel DiseaseIndication
ulcerative colitisIndication
Chronic Nonbacterial OsteomyelitisIndication
Low Back PainIndication
Major Depressive DisorderIndication
AneurysmIndication
strokeIndication
VasculitisIndication
Tumor Necrosis Factor-alphaIndication
Retinal DetachmentIndication
Proliferative VitreoretinopathyIndication
efficacyIndication
Rheumatoid ArthritisIndication
SelfIndication
BiologicsIndication
MesalazineIndication
COVID-19Indication
SarcoidosisIndication
Behcet's DiseaseIndication
Hematopoietic and Lymphoid Cell NeoplasmIndication
Malignant Solid NeoplasmIndication
PneumonitisIndication
SchizophreniaIndication
Therapeutic Drug MonitoringIndication
MRNI-FIC ScoreIndication
Arteritis, Giant CellIndication
Takayasu arteritisIndication
Cogan SyndromeIndication
Relapsing polychondritisIndication
Cryoglobulinemic VasculitisIndication
Henoch-Schönlein purpuraIndication
polyarteritis nodosaIndication
Cutaneous Polyarteritis NodosaIndication
Immune suppressionIndication
ChildhoodIndication
OnlyIndication
Glaucoma following surgeryIndication
Melanoma stage IIIIndication
melanomaIndication
Skin Cancer Stage IIIIndication
Skin CancerIndication
Drug-Induced ColitisIndication
Drug ToxicityIndication
Immune-related Adverse EventIndication
Atopic DermatitisIndication
Metastatic MelanomaIndication
Indeterminate ColitisClinical trial
PERFUSE - One-year Persistence to Treatment of Patients Receiving Flixabi or Imraldi: a French Cohort StudyStatus: Completed, Estimated PCD: 2022-06-30
Clinical trial
swiTching From etAnercept to iNfliximab in the Treatment of Moderate to Severe Psoriasis; a Multi-center, Open Label Trial evaluatinG the Efficacy, tOlerance and Safety (TANGO)Status: Completed, Estimated PCD: 2009-10-01
Clinical trial
A Multi-Center Registry Study of Infliximab in the Treatment of Chinese Children With Crohn's DiseaseStatus: Completed, Estimated PCD: 2023-09-12
Clinical trial
The Role of Inflammation in Cognitive Dysfunction in Acute Depression as Determined by Experimental Inhibition of Tumor Necrosis Factor-alpha Signaling in a Randomized Controlled Trial.Status: Not yet recruiting, Estimated PCD: 2027-09-01
Clinical trial
Subcutaneous Infliximab After A Previous Intravenous Dose OptimizationStatus: Active (not recruiting), Estimated PCD: 2026-05-01
Clinical trial
Top-down Infliximab Study in Kids With Crohn's DiseaseStatus: Completed, Estimated PCD: 2019-12-01
Clinical trial
CHronic Nonbacterial Osteomyelitis International Registry (CHOIR)Status: Recruiting, Estimated PCD: 2028-08-01
Clinical trial
The Effect of Infliximab in Patients With Chronic Low Back Pain and Modic Changes. A Randomized, Double Blind, Placebo-controlled, Multicenter TrialStatus: Completed, Estimated PCD: 2023-07-27
Clinical trial
A Randomized Control Study to Examine the Influence of a Healthy Diet on Moderate to Severe Ulcerative Colitis Patients Undergoing Second Line Induction With Biological Medications Tofacitinib, Ustekinumab or VedolizumabStatus: Completed, Estimated PCD: 2023-12-07
Clinical trial
EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis : A Double Blinded Randomized Clinical TrialStatus: Recruiting, Estimated PCD: 2024-01-04
Clinical trial
Therapeutic Monitoring of Infliximab and Adalimumab in Pediatric Chronic Inflammatory Diseases: Innovative Pharmacological Strategies for Predicting Response and Adverse EffectsStatus: Recruiting, Estimated PCD: 2024-04-15
Clinical trial
De-escalation of Anti-TNF Therapy in Adolescents and Young Adults With IBD With Tight Faecal Calprotectin and Trough Level MonitoringStatus: , Estimated PCD: 2025-03-01
Clinical trial
Inflammation-Induced CNS Glutamate Changes in DepressionStatus: Terminated, Estimated PCD: 2019-11-27
Clinical trial
Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis: a Multicenter, Prospective, Randomized, Controlled Clinical StudyStatus: Recruiting, Estimated PCD: 2024-01-15
Clinical trial
Infliximab Therapy for Dolichoectactic Vertebrobasilar AneurysmsStatus: , Estimated PCD: 2025-06-01
Clinical trial
Treatment of Proliferative Vitreoretinopathy With Intravitreal InfliximabStatus: Completed, Estimated PCD: 2023-11-10
Clinical trial
Multisystem Inflammatory Syndrome Therapies in Children (MISTIC) Comparative Effectiveness StudyStatus: Completed, Estimated PCD: 2023-12-22
Clinical trial
Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's DiseaseStatus: Recruiting, Estimated PCD: 2027-03-31
Clinical trial
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Multi-Center, Prospective Study to Discover a Companion Diagnostic for Biologics Targeting TNFStatus: Completed, Estimated PCD: 2023-10-31
Clinical trial
Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative ColitisStatus: Active (not recruiting), Estimated PCD: 2022-11-07
Clinical trial
Randomized Master Protocol for Immune Modulators for Treating COVID-19Status: Completed, Estimated PCD: 2022-01-30
Clinical trial
Assessment of Trough Levels and Efficacy of Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.Status: Completed, Estimated PCD: 2023-03-30
Clinical trial
Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES STUDY)Status: Completed, Estimated PCD: 2021-06-21
Clinical trial
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE TrialStatus: , Estimated PCD: 2024-12-31
Clinical trial
Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel DiseaseStatus: Completed, Estimated PCD: 2021-02-01
Clinical trial
Multicenter, Randomized, Prospective Trial Comparing the Efficacy and Safety of Infliximab to That of Cyclophosphamide in Severe Behçet's Disease. ITAC : Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet DiseaseStatus: Completed, Estimated PCD: 2021-12-24
Clinical trial
Impact of Early Proactive Therapeutic Drug Monitoring on the Durability and Efficacy of Infliximab Therapy in Pediatric Inflammatory Bowel Disease: a Multicenter Open-label Randomized-control TrialStatus: Recruiting, Estimated PCD: 2024-01-31
Clinical trial
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 PneumonitisStatus: Terminated, Estimated PCD: 2023-12-21
Clinical trial
A Randomized, Controlled, Multicenter, Open Label Phase II Clinical Study to Evaluate Infliximab in the Treatment of Patients With Severe COVID-19 DiseaseStatus: Completed, Estimated PCD: 2023-03-31
Clinical trial
Targeting Inflammation-Induced Changes in Brain Reward Signaling and Motivational Deficits in Patients With Schizophrenia Using an Anti-Inflammatory Challenge.Status: Recruiting, Estimated PCD: 2028-03-01
Clinical trial
Efficacy of Infliximab Treatment Based on TDM (Therapeutic Drug Monitoring) in Adult Patients With Active Perianal Fistulizing Crohn's DiseaseStatus: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
Biologics in Refractory Vasculitis (BIOVAS): A Pragmatic, Randomised, Double-blind, Placebo-controlled, Modified-crossover Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis in Adults and ChildrenStatus: Active (not recruiting), Estimated PCD: 2023-11-30
Clinical trial
PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative ColitisStatus: Completed, Estimated PCD: 2021-10-01
Clinical trial
Comparison of Short and Long-term Efficacy Between Infliximab and Adalimumab on Patients With Ulcerative Colitis - a Retrospective Observational Multicenter Cohort StudyStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Combination Therapy of Infliximab and Immunosuppressives for Pediatric Crohn's DiseaseStatus: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
Topical Infliximab in Eyes With Penetrating KeratoplastyStatus: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe ColitisStatus: Completed, Estimated PCD: 2022-06-01
Clinical trial
Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis (COMBO-UC)Status: Not yet recruiting, Estimated PCD: 2028-04-30
Clinical trial
Stopping Tumor Necrosis Factor-Alpha Inhibitors in Rheumatoid Arthritis (STARA) Clinical TrialStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Phase II Study of Infliximab for the Treatment of Immune Checkpoint Inhibitor ColitisStatus: Recruiting, Estimated PCD: 2030-06-30
Clinical trial
Safety, Efficacy, and Cost-effectiveness of a Reduced Infliximab Infusion Time ProtocolStatus: Completed, Estimated PCD: 2023-05-04
Clinical trial
ADVANCED-UC TRIAL: AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis - A Randomized Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2024-07-01
Clinical trial
Treatment and Fate in Fistulizing Crohn's Disease in a Pediatric PopulationStatus: Active (not recruiting), Estimated PCD: 2013-07-01
Clinical trial
Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic EvaluationStatus: Completed, Estimated PCD: 2021-12-31
Clinical trial
Preemptive HLADQA1*05 Genotyping for the Use of Infliximab in Chinese Crohn's Disease：A Multicenter, Prospective, Controlled, Randomized StudyStatus: Not yet recruiting, Estimated PCD: 2026-05-31
Clinical trial
Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease by Proteomic and Mass Cytometry ApproachesStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Systematic Profiling of Anti-cytokine Signatures in the Treatment of Chronic Inflammatory Skin DisordersStatus: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Phase II Study of PD-1 Blockade With or Without LAG-3 Inhibition in Combination With Infliximab for the Treatment of Metastatic Melanoma and Prevention of Adverse EventsStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
First-line Treatment With Infliximab Versus Corticosteroids in Children With Newly Diagnosed Moderate to Severe Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel DiseaseStatus: Active (not recruiting), Estimated PCD: 2037-11-15
Clinical trial
A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisStatus: Active (not recruiting), Estimated PCD: 2024-06-20
Clinical trial
Randomized, Multicenter Study to Investigate the Efficacy of Dashboard Driven Individualized Dosing of Infliximab Compared To Standard Dosing During the Induction in Patients With Acute Severe Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2024-12-31
Document
DailyMed Label: REMICADEOrganization
Janssen Biotech, Inc.Organization
Organon LLCDocument
DailyMed Label: RenflexisOrganization
Merck Sharp & Dohme LLCDocument
DailyMed Label: AVSOLAOrganization
Amgen IncDocument
DailyMed Label: INFLIXIMABDocument
DailyMed Label: INFLECTRAOrganization
Pfizer Laboratories Div Pfizer IncOrganization
Merck Sharp & Dohme LLC